Alison Mosca - 09 Jan 2026 Form 4 Insider Report for Clene Inc. (CLNN)

Reporting relationship: Director
Issuer ticker: CLNN
Reported as of: 09 Jan 2026
Net transaction value: +$100,002
SEC form: 4
Accepted by SEC: 13 Jan 2026, 18:46:50 UTC
Prior SEC filing: 14 Nov 2025
Next SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Alison Mosca

Key filing fact

Alison Mosca filed Form 4 for Clene Inc. (CLNN) on 13 Jan 2026.

Key facts

This page summarizes Alison Mosca's Form 4 filing for Clene Inc. (CLNN).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 13 Jan 2026, 18:46.

Change

Previous filing in this sequence was filed on 14 Nov 2025.
Current net transaction value: +$100,002.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835537 Primary reporting owner

Mosca Alison

Relationship: Director
Address: 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Signature: /s/ Alison Mosca
Signature date: 13 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLNN transaction

Common Stock

Other

Transaction value: $0
Shares: -57,219
Change %: -18%
Price: $0.000000
Shares after: 263,833
Date: 09 Jan 2026
Ownership: By LLC
Footnotes: F1, F2

CLNN transaction

Common Stock

Award

Transaction value: $100,002
Shares: +16,667
Change %: +6.3%
Price: $6.00
Shares after: 280,500
Date: 13 Jan 2026
Ownership: By LLC
Footnotes: F2, F3, F4

CLNN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,973
Date: 09 Jan 2026
Ownership: Direct

CLNN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 150,333
Date: 09 Jan 2026
Ownership: By LP
Footnotes: F5

CLNN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 72,997
Date: 09 Jan 2026
Ownership: By Trust
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLNN transaction Derivative

Tranche B Warrants (Right to buy)

Other

Transaction value: $0
Shares: -57,219
Change %: -48%
Price: $0.000000
Shares after: 62,500
Date: 09 Jan 2026
Ownership: By LLC
Underlying class: Common Stock
Underlying amount: 57,219
Exercise price: $30.00
Footnotes: F1, F2, F7

CLNN transaction Derivative

Tranche A Warrants (Right to buy)

Other

Transaction value: $0
Shares: -57,219
Change %: -48%
Price: $0.000000
Shares after: 62,500
Date: 09 Jan 2026
Ownership: By LLC
Underlying class: Common Stock
Underlying amount: 57,219
Exercise price: $22.00
Footnotes: F1, F2, F8

CLNN transaction Derivative

Series A Warrants (Right to buy)

Award

Transaction value
Shares: +20,000
Change %
Price
Shares after: 20,000
Date: 13 Jan 2026
Ownership: By LLC
Underlying class: Common Stock
Underlying amount
Exercise price: $6.00
Footnotes: F2, F4, F9, F10

CLNN transaction Derivative

Series B Warrants (Right to buy)

Award

Transaction value
Shares: +46,667
Change %
Price
Shares after: 46,667
Date: 13 Jan 2026
Ownership: By LLC
Underlying class: Common Stock
Underlying amount
Exercise price: $6.00
Footnotes: F2, F4, F11, F12

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 12 footnotes

Footnote F1

The transaction reported on this line represents a distribution in kind by the limited liability company to a limited partner for no consideration.

Footnote F2

The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

Footnote F3

Kensington Clene 2021, LLC entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 16,667 shares of the Company's common stock, Series A Warrants to purchase 20,000 shares of the Company's common Stock and Series B Warrants to purchase 46,667 shares of the Company's common stock, closing effective January 13, 2026.

Footnote F4

The price of each Unit is $6.50; one Unit consists of one share of Common Stock of Clene Inc., one Series A Warrant and one Series B Warrant.

Footnote F5

The securities are owned by the Kensington Investments, L.P. Ms. Mosca is the chief executive officer of Kensington Investments, L.P. The shares owned by the Kensington Investments, L.P. may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Investments, L.P., for which she does not have a pecuniary or profits interest.

Footnote F6

The securities are owned by the Robert C. Gay 1998 Family Trust. Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust. The shares owned by the Robert C. Gay 1998 Family Trust may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust.

Footnote F7

The Tranche B Warrants will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the FDA approval of a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

Footnote F8

The Tranche A Warrants will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the FDA accepts a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

Footnote F9

The exercise price for each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drugs User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement") or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.

Footnote F10

The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

Footnote F11

The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.

Footnote F12

The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.